Related Experiment Video
Updated: Apr 28, 2026
Methodology for Sputum Induction and Laboratory Processing
Published on: December 17, 2017
Intravenous salbutamol for childhood asthma: evidence-based medicine?
E S Starkey1, H Mulla2, H M Sammons3
1Department of Paediatrics, Royal Derbyshire Hospital, Derby, UK.
Insights
Intravenous salbutamol is used for severe pediatric asthma, but evidence for its effectiveness is limited. Current dosing may increase risks of adverse events like lactic acidosis and tachycardia.
Area of Science:
- Pediatric Pulmonology
- Clinical Pharmacology
- Emergency Medicine
Background:
- Intravenous salbutamol is a common treatment for severe pediatric asthma unresponsive to standard inhaled therapies.
- Limited clinical trial data exists to support the effectiveness of intravenous salbutamol in this patient population.
- Concerns are raised regarding potentially excessive dosing recommendations for intravenous salbutamol in children with acute asthma.
Purpose of the Study:
- To review the clinical pharmacology and toxicology of salbutamol.
- To evaluate the existing evidence for the use of intravenous salbutamol in acute pediatric asthma.
- To identify gaps in the evidence base concerning intravenous salbutamol treatment in children.
Main Methods:
- Literature review of clinical pharmacology and toxicology studies.
- Analysis of evidence regarding the efficacy and safety of intravenous salbutamol in acute asthma.
- Identification and discussion of research gaps.
Main Results:
- Limited clinical trial data supports the effectiveness of intravenous salbutamol in severe pediatric asthma.
- Current dosing recommendations may be excessive, increasing the risk of adverse reactions.
- Adverse events like lactic acidosis and tachycardia can worsen respiratory failure.
Conclusions:
- Further clinical trials are needed to establish the efficacy and optimal dosing of intravenous salbutamol in children with severe asthma.
- The potential for adverse events necessitates careful consideration of current treatment protocols.
- Evidence gaps highlight the need for more research to ensure safe and effective use of intravenous salbutamol.
Abstract:
Intravenous salbutamol is commonly used to treat children with severe asthma unresponsive to inhaled β2-agonist therapy. However, in this setting, there is little clinical trial data demonstrating its effectiveness. Additionally, there are significant concerns that intravenous salbutamol-dosing recommendations for children with acute asthma are excessive, and unnecessarily raise the potential for adverse reactions, such as lactic acidosis and tachycardia which, by increasing respiratory workload, exacerbate respiratory failure. Here, we review salbutamol clinical pharmacology and toxicology, evidence relating to its use in acute asthma and highlight gaps in the evidence base.
Related Concept Videos
01:30Asthma-IV: Diagnostic and Management
Clinical Assessment for Asthma:
This is the first step in diagnosing and managing asthma. It includes:
01:23Inhaled Medications
01:25Antiasthma Drugs: β2-Adrenoceptor Agonists
One class of bronchodilators includes β2-adrenoceptor agonists. These agents target the β2-adrenoceptors located on bronchial smooth muscle cells. By stimulating these receptors, β2-agonists induce...
01:30Asthma-IV: Nursing Management
First, in...
01:20Asthma: Pathogenesis and Management
Asthma is classified as allergic and non-allergic. Allergens such as dust mites, pollen, and pet dander trigger allergic asthma, while factors like cold air, intense emotions, or exercise can induce non-allergic asthma.
01:30Adrenergic Agonists: Therapeutic Uses
Emergency and Intensive Care Unit (ICU) applications: Pressor agents increase blood pressure, heart rate, and contractility in shock and organ failure situations. Dopamine can induce vasodilation and stimulate adrenoceptors. Endogenous catecholamines are effective in treating cardiogenic shock. α2-agonists like clonidine can reverse anesthesia-induced hypertension.
Allergies and...